"The last 12 months have been successful for Quantifi and the opening of our expanded London office is a response to the increased demand we are witnessing across our entire product suite," states Rohan Douglas, CEO of Quantifi. "I'm particularly excited with the uptake in demand for our OIS/CSA analytics and our Counterparty Risk solutions. A strong endorsement of our success in the CVA and Counterparty Risk space is the number of new clients in all regions that went into production in 2012."

Over the last year, Quantifi has released three major product versions designed to address the increasing complexities of OTC derivatives valuation and counterparty risk management, as well as respond to client demand for expanded asset coverage including FX, equities and commodities. At the same time, Quantifi continued to deliver market leading technology for advanced risk management and analytics while providing the superior, robust performance and intuitive user experience its clients rely on.

Kathleen Del Duca, Director of Operations for Quantifi, comments, "We are delighted with the 40% EMEA revenue growth we have experienced this year, which we have achieved through exceptional client service and by attracting new clients in major markets globally. Furthermore, given the growth of our EMEA client base and expanded EMEA operations, the move into larger office space is a natural step in our growth strategy as we look to further develop our footprint across the region."

Further testimony to Quantifi's success is the industry accolades the firm received in the past year. Recognised for excellence and innovation in adapting to the fast-changing risk management and OTC derivatives landscape, Quantifi was awarded 'Risk Management Technology Product of the Year' by Risk Magazine's 2012 Risk Awards, 'Technology Company of the Year' by Asia Risk Awards 2012 and 'Risk Management Software of the Year' by CIR Risk Management Awards 2012.

Douglas continues, "2013 promises to be a year of significant change and opportunity for the OTC markets. This is a time when it is critical for firms to stay ahead of market changes to be able to seize opportunities and minimise risk. Our close partnership with clients and our significant investment in research and development allows us to innovate rapidly and help our clients achieve this goal."